Cristi Sandu is an accomplished scientist with extensive experience in bioassay development. Since 2019, he has led the late-stage bioassay team at Regeneron Pharmaceuticals, where he is responsible for developing potency bioassays and supporting the late-stage pipeline with important potency data. Prior to his role at Regeneron, Cristi worked as a scientist at Firmenich, focusing on cell-based assays for olfactory G-protein-coupled receptors (GPRs) and deorphanization efforts. From 2009 to 2016, Cristi conducted postdoctoral research at The Rockefeller University and the Howard Hughes Medical Institute (HHMI), where his research centered on mechanisms of programmed cell death, utilizing approaches spanning from model organisms to chemical genetics, developing reporter bioassays, conducting large-scale high-content small molecule screening, and performing structure-activity relationship (SAR) studies. Cristi earned his Ph.D. in 2002 from Freiburg University, where he explored the biochemistry of microbial nicotine degradation. His diverse experience and deep knowledge in life sciences research make him a valuable asset to the scientific community.